Orphazyme A/S (1TB.F)
| Previous Close | 0.2566 |
| Open | 0.2516 |
| Bid | 0.2536 x 70000 |
| Ask | 0.2714 x 70000 |
| Day's Range | 0.2516 - 0.2864 |
| 52 Week Range | 0.1584 - 6.0450 |
| Volume | |
| Avg. Volume | 500 |
| Market Cap | 10.01M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4350 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Resolutions passed at the Annual General Meeting
Orphazyme A/SCompany announcementNo. 33/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, June 29, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2021 and 2022 Took note of the Board of Directors’ report on the Company’s activities in the past financial year;Adopted the Company’s Annual Report 2021;Adopted that the loss related to the financial year 2021 is carried forward;Appr
- GlobeNewswire
Updated notice to holders of ADSs regarding termination of Deposit Agreement
Orphazyme A/SCompany announcement No. 32/2022www.orphazyme.comCompany Registration No. 32266355 NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”) REPRESENTING DEPOSITED COMMON SHARES OF:ORPHAZYME A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 687305102 AND UNDERLYING ISIN: DK0060910917 Copenhagen, Denmark, June 20, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares
- GlobeNewswire
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Orphazyme A/SCompany announcementNo. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355 [Correction: Hereby including the ESEF versions] Copenhagen, Denmark, June 7, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report. In 2021, and until recently, the primary focus of Orphazyme was on seeking marketing authorization in the United States
